miR-410 enhanced hESC-derived pancreatic endoderm transplant to alleviate gestational diabetes mellitus

Yang Mi1, Na Guo1, Tongqiang He1, Jing Ji1, Zhibin Li1 and Pu Huang2

1Obstetrical Department, Northwest Women’s and Children’s Hospital, 1616 Yanxiang Road, Xi’an, Shanxi Province 710061, China
2Department of Obstetrics and Gynecology, The First Affiliated Hospital of Xi’an Jiaotong University College of Medicine, 277 Yanta West Road, Xi’an, Shanxi Province 710061, China

Abstract

Gestational diabetes mellitus (GDM) is a condition commonly encountered during mid to late pregnancy with pathologic manifestations including hyperglycemia, hyperinsulinemia, insulin resistance, and fetal mal-development. The deficit and dysfunction of insulin secreting β-cells are signature symptoms for GDM. Pancreatic progenitors derived from human embryonic stem cells (hESCs) were shown to be able to effectively treat diabetes in mice. In this study, we first identified that microRNA-410 (miR-410) directly targets lactate dehydrogenase A (LDHA), a gene selectively repressed in normal insulin secreting β-cells. hESCs that can be induced to express miR-410 hence keeping LDHA levels in check were then differentiated in vitro into pancreatic endoderm, followed by transplantation into db/+ mouse model of GDM. The transplant greatly improved glucose metabolism and reproductive outcome of the pregnant females suffering from GDM. Our findings describe for the first time the method of combining miRNA with hESCs, providing proof of concept by employing genetically modified stem cell therapy for treating GDM.

Key Words
- microRNA-410
- gestational diabetes mellitus
- human embryonic stem cell
- pancreatic endoderm
- C57BL/KsJ-Lepdb/+ mouse

Introduction

Gestational diabetes mellitus (GDM) is a disease resulting from insufficient insulin production during pregnancy (American Diabetes Association 2004). GDM patients are commonly diagnosed in the second trimester during pregnancy, usually showing no prior sign of diabetes. Approximately 3–5% of GDM patients also remain diabetic after pregnancy (Perkins et al. 2007). Besides maternal diabetic symptoms, GDM is also characterized by fetal mal-development (Gardosi & Francis 2009). The mechanisms underlying GDM remain largely unexplored, although its origins are thought to be multifactorial involving both genetic and environmental factors (Cypryk et al. 2008). Mutations in the pancreatic β-cell KATP channel subunits Kir6.2 (KCNJ11) and SUR1 (ABCC8) were reported to cause diabetes mellitus and hyperinsulinism (Gloyn et al. 2006). High-saturated-fat diet was also shown to be able to induce glucose abnormalities among pregnant women (Bo et al. 2001). The C57BL/KsJ-Lepdb/+ (abbreviated as db/+) mouse serves as a promising heterozygous mutant animal model closely
mimicking human GDM symptoms (Kaufmann et al. 1981). Prior to pregnancy, they exhibited largely normal glucose tolerance until late gestation (Ishizuka et al. 1999, Lambin et al. 2007). Fetal development was also defective with fetus weight at term increased by 5–8% (Lawrence et al. 1989, Yamashita et al. 2001).

Advances in stem cell technology have provided exciting development in diabetes treatment in animal models. Human embryonic stem cells (hESCs) were used to differentiate the pancreatic endoderm (PE) capable of treating diabetic mice (Kroon et al. 2008). Pagliuca et al. (2014) have also demonstrated in a very recent study that a large scale in vitro differentiation of human induced pluripotent stem cells (hiPSCs) to generate glucose-responsive insulin-producing pancreatic β-cells. These cells were able to secret human insulin into the serum and ameliorate hyperglycemia after being transplanted in diabetic mice.

MicroRNAs (miRNAs or miRs) are 21–25 nucleotide long, small non-coding RNA molecules. miRNAs recognize specific and complementary sequences predominantly found in the 3′-UTR on target mRNAs, either repressing translation or degrading these mRNAs (Bartel 2004, 2009). In the development of diabetes, various miRNAs were found to play different functions and roles, and may serve as potential biomarkers (Higuchi et al. 2015, Seyhan 2015). miR-146b was reported to regulate retinal inflammation through suppressing adenosine deaminase-2 in diabetes (Fulzele et al. 2015). miR-192, miR-194, miR-204, and miR-215 were found enriched in human kidney (Sun et al. 2004), where they target genes important for kidney development and function (Oghbaei et al. 2015). However, to the best of our knowledge, there has been no study on the potential involvement in GDM.

In this study, we first identified miR-410 as a direct regulator targeting human lactate dehydrogenase A (LDHA). LDHA is usually kept in low expression level in insulin-secreting β-cells (Sekine et al. 1994), and its overexpression affects glucose-induced insulin secretion (Ainscow et al. 2000). We then transduced miR-410 into hESCs using a Tet-on system. These miR-410 transduced hESCs were further differentiated to PE cells and transplanted into the db/+ female mice. We then assessed the effect of the PE transplant on GDM symptoms and fetal development of the db/+ female mice. The transplant greatly improved glucose metabolism and reproductive outcome of the pregnant db/+ females. In our present study, we aimed to provide proof-of-concept and experimental methods of combining miRNA technique with stem cell therapy in treating GDM.

Materials and methods

miRNA transfection

Human shMIMIC inducible lentiviral miR-410 was purchased from GE Lifesciences (Pittsburgh, PA, USA: product ID: VSH6904-224634910) along with SMARTvector Inducible Non-targeting Control (product ID: VSC6572). Both miRNA and negative control were transduced into cell lines according to manufacturer’s instructions.

Luciferase reporter assay

The putative miR-410 binding site at the 3′-UTR of LDHA was cloned downstream of a SV40 promoter-driven Gaussia luciferase (GLuc) reporter gene in a pEZX-MT05 vector (GeneCopoeia, Rockville, MD, USA). Mutant forms of the luciferase constructs were also generated using standard PCR-based overlap-extension protocols. For luciferase reporter assay, HeLa cells (3×10⁴) were plated in a 24-well plate and then co-transfected with 400 ng of either miR-410 or miR-control, 200 ng of either WT luciferase constructs, using Lipofectamine 2000 (Invitrogen) according to manufacturer’s instruction. Cells were collected 48 h after transfection and analyzed using the Dual-Luciferase Reporter Assay System (Promega). The pEZX-MT05 vector also contains a secreted alkaline phosphatase (SeAP) reporter driven by a CMV promoter and served as the internal control to correct the differences in transfection and harvest efficiencies.

Quantitative RT-PCR

Total RNA was isolated from cells using the RNaseasy MiniPrep Kit (Qiagen). One microgram of total RNA was reverse-transcribed with Superscript II First-Strand Synthesis Kit (Life Technologies) as recommended by the manufacturer. GAPDH mRNA levels were measured for normalization and all data were presented as relative expression.

In vitro differentiation of hESCs

H1 hESC lines were cultured using mTeSR1 medium (STEMCELL Technology, Vancouver, BC, Canada) on Matrigel (BD Biosciences, San Jose, CA, USA) coated culture plates and passaged as previously described (Ludwig et al. 2006). The four-stage differentiation protocol was carried out as previously described (Kroon et al. 2008).

In stage 1, H1 hESCs were transitioned to definitive endoderm (DE). At 75% confluency, H1 hESCs were
washed briefly with 1× PBS, then cultured with RPMI medium containing 100 ng/ml activin supplemented with 0, 0.2, and 0.2% (v/v) FBS (Hyclone, Pittsburgh, PA, USA) on days 1–3 respectively. Wnt3a was added to day 1 medium at final concentration of 25 ng/ml to improve the transition.

In stage 2, DE was further differentiated to endoderm of the primitive gut (PG) tube. DE was cultured for 3 days with RPMI medium containing 2% FBS and supplemented with 50 ng/ml FGF10 and 20 ng/ml KAAD-cyclopamine (CYC). In stage 3, PG cells were treated with 0.5 μM retinoic acid (RA) together with 20 ng/ml CYC and 50 ng/ml FGF10 in DMEM supplemented with 1% B27 (Invitrogen) for 3 days to become PDX1-expressing posterior foregut (PF) endoderm cells.

In stage 4, PF cells were further transformed into pancreatic and endocrine lineages. During 3 days of culture, RA was removed from the medium and 1 μM DAPT and 50 ng/ml exendin-4 were added into the medium.

Cells after stage 4 were characterized by co-expression of PDX1, FOXA2, and SOX9, and were referred as PE.

**Immunofluorescence**

Cells were washed with 1× PBS for three times and fixed with 4% paraformaldehyde for 10 min at room temperature, followed by 10 min permeabilization with 0.2% Triton X-100 in PBS. The cells were blocked for 1 h with 5% goat serum and 2% BSA. Diluted primary antibodies were then added to the culture and incubated at 4°C overnight. IgG isotype control mouse and rabbit polyclonal IgG (Abcam, Cambridge, MA, USA) were used as control for staining respectively. After four washes with 1× PBS, diluted secondary antibodies against specific primary antibodies were added and incubated in the dark at room temperature for 1 h. 4′,6-Diamidino-2-phenylindole (DAPI, Invitrogen) was added 10 min before the final wash. Pictures were taken under fluorescent microscope. The primary antibodies used were OCT4 (mouse, 1:200 dilution, Santa Cruz), SOX9 (rabbit, 1:300 dilution, Santa Cruz), PDX1 (rabbit, 1:300 dilution, Santa Cruz), and FOXA2 (mouse, 1:200 dilution, Santa Cruz). The secondary antibodies used were Alex 488 (goat anti-mouse, 1:500, Life Technologies) and Alexa 568 (goat anti-rabbit, 1:500, Life Technologies).

**Western blotting**

Cell lysate was added into 20 μl 2× sample loading buffer (0.125 M of 5 M Tris–HCl, Amresco, Framingham, MA, USA; 20% glycerol, Usb; 4% of 10% SDS, Amresco; 1% β-mercaptoethanol, Amresco; and 0.2% of 0.05% (w/v) bromophenol blue, Sigma) and boiled for 5 min before loading. Proteins were separated by SDS–PAGE, transferred to Immobolon-P membrane (Millipore, Cambridge, MA, USA), and were probed with antibodies against LDHA and β-actin as indicated. All antibodies were purchased from Cell Signaling (Beverly, MA, USA). The results were visualized using ECL Kit (Abcam) and observed by GeneGnome machine (Syngene, Cambridge, UK).

**Glucose-stimulated insulin secretion**

Glucose-stimulated insulin secretion assay was performed according to previously established methods (Pagliuca et al. 2014). Briefly, PE clusters were washed with Krebs buffer and were then pre-incubated in 2 mM glucose for 2 h to remove residual insulin. Clusters were then washed twice, incubated in 2 mM glucose for 30 min, and supernatant collected. Then clusters were washed again, incubated in 20 mM glucose for another 30 min, and supernatant collected. Clusters were then dispersed into single cells and cell number was counted. Supernatant samples containing secreted insulin were processed using the 1-2-3 UltraSensitive Mouse Insulin ELISA Kit (ALPCO Diagnostics, Salem, NH, USA).

**LDHA activity assay**

LDHA activity in hESC-derived PE clusters, in the presence or absence of doxycycline, was assayed using LDH Activity Assay Kit (Sigma) according to manufacturer’s instructions.

**Animals and transplant of hESC-derived cells**

The care and use of animals in this study followed the guidelines and protocol approved by the Institutional Animal Care and Use Committee (IACUC) of The First Affiliated Hospital of Xi’an Jiaotong University. The IACUC members approved this study. All efforts were made to minimize the number of animals used and their suffering. Six-week-old mice were housed with fresh food and water, temperature (22±2°C), humidity (40–60%), and light (12 h light:12 h darkness cycle) for 2 weeks. The rodent diet with 18% protein, 5% fat was provided (Harlan Teklad, Madison, WI, USA). Mice were arbitrarily assigned to one of four groups in a generalized randomized complete block design, with 20 mice/group: WT female mice receiving sham transplants and administered with doxycycline (WT sham+dox); db/+ female
mice receiving sham transplants and administered with doxycycline (db/+ sham + dox); db/+ females receiving PE transplants and administered with doxycycline (db/+PE + dox); and db/+ females receiving PE transplants but without doxycycline administer (db/+PE− dox). Doxycycline was administered in drinking water at a concentration of 1 mg/ml, supplemented with 1% (wt:vol) sucrose to mask the bitter taste. Mice were anesthetized with inhalable isoflurane and received transplants of 5 x 10⁶ stage 4 hESC-derived PE cells under the left kidney capsule. After transplant all mice were treated with oral enrofloxacin (Bayer Animal Health) for 1 week (100 mg/ml in drinking water).

Body weight, blood glucose, and plasma insulin

Body weight, blood glucose, and plasma insulin were measured prior to PE transplant (day 0), 4 weeks after transplant (day 28), gestation day 0 (GD0), GD10, and GD20. Body weight was measured on a top-loading balance (Accu-622; Fisher Scientific, Waltham, MA, USA), and nonfasting maternal blood samples were obtained via tail venipuncture to determine insulin and glucose levels. Blood glucose levels were determined by glucometer (Lifescan Surestep, Fisher Scientific). Plasma insulin levels were quantified by 1-2-3 UltraSensitive Mouse Insulin ELISA Kit (ALPCO Diagnostics), which detects both insulin 1 and 2.

Body composition and metabolic assessment

Body composition (lean mass and fat content) was measured using a dual-energy X-ray absorptiometry method (Sabre Bone Densitometry, Norland Med, White Plains, WI, USA). Plasma leptin was assayed using mouse leptin ELISA Kits (Crystal Chem, Inc., Downers Grove, IL, USA) respectively. Plasma free fatty acids (FFAs) and triglycerides (TGs) were assessed using Wako NEFAC (Wako Chemicals USA, Inc., Richmond, VA, USA) and Free Glycerol Reagent (Sigma).

Liver weight and liver TG content

Mice were sacrificed to dissect and weigh liver tissue at the end of the 16-week experiment. Liver TG content was measured by homogenizing liver in chloroform/methanol (vol:vol, 2:1) and incubated at room temperature for 4 h. The tissue lysate was then dried in air and re-suspended by KOH (3 M) for 1 h incubating at 70 °C. MgCl₂ was used to neutralize the lysate and TG assay was performed as previously described.

Statistical analysis

All data were analyzed using Prism Software version 5 (GraphPad, San Diego, CA, USA). Data are presented as mean±s.d. Comparisons of two groups were made by unpaired Student’s t-test and one-way ANOVA. P<0.05 was considered as statistical significant.

Results

miR-410 directly targets and down-regulates LDHA

Using www.microrna.org as our resource, we identified miR-410 as a potential regulator of LDHA mRNA, with one binding site in the 3'-UTR of LDHA (NM_005566; Fig. 1A and Supplementary Figure 1, see section on supplementary data given at the end of this article). To confirm LDHA is a bona fide target of miR-410, luciferase reporter assay was performed, using sequences from original 3'-UTR on LDHA mRNA as well as a mutated version (Fig. 1B). As a result, luciferase activity was dramatically reduced by co-transfection of miR-410, to <30% of non-targeting control (NC) transfected levels (Fig. 1C), indicating that the LDHA 3'-UTR was indeed a direct target of miR-410.

We next transfected miR-410 into HeLa cell lines and analyzed both mRNA and proteins levels of LDHA. Compared with miR-NC transfections, introducing miR-410 significantly reduced mRNA levels of LDHA (Fig. 1D), suggesting regulation of LDHA by miR-410 occurred mainly through mRNA degradation. Using antibody against LDHA, we were able to detect that its protein levels were also significantly down-regulated in miR-410 transfected HeLa cells, but not in miR-NC transfected experiment (Fig. 1E). Taken together, the preceding results clearly demonstrated that miR-410 down-regulated both the mRNA and protein levels of LDHA.

miR-410 suppresses LDHA expression in hESC-derived PE cells

H1 hESC was first transduced with miR-410 in a Tet-on 3G induction system to become miR-H1 hESC line. Without doxycycline induction, miR-H1 can readily maintain their pluripotency and other typical characteristics of hESC (data not shown). Next, following previously established four-stage differentiation protocol (Kroon et al. 2008), we differentiated miR-H1 hESCs to PE (miR-PE) (see ‘Materials and methods’). Using immunofluorescence, we were able to confirm the cells expressed appropriate markers throughout the differentiation. At the beginning of
stage 1, H1 hESC expressed the pluripotency marker OCT4 (Niwa et al. 2000; Fig. 2A, top row). At stage 4, cells lost OCT4 and exhibited PDX1 expression (Fig. 2A, bottom row), a key pancreatic transcription factor (Jensen 2004). We further confirmed the cell lineage by staining the stage 4 hESC-derived cells with antibodies against FOXA2 and SOX9, another two signature transcription factors characterization of PE (Jensen 2004, Jorgensen et al. 2007), and they were both expressed in these cells (Fig. 2B). Next using quantitative RT-PCR, we quantified the relative expression levels of the previous marker genes, showing the differentiated cells had completely shut down OCT4 expression, and greatly increased mRNA levels of PDX1, FOXA2, and SOX9 (Fig. 2C). Therefore, the hESC-derived cells generated by our four-stage protocol closely matched committed PE in the embryo (Zorn & Wells 2007).

Induced by doxycycline, miR-H1-ESCs showed significant decrease of LDHA mRNA levels compared to H1 hESCs without miR transduction. However, without doxycycline or miR-410, no significant difference in LDHA mRNA level was found compared with the control (Fig. 2D). Using western blot, we also found a decreased LDHA protein level when miR-PE cells were induced by doxycycline (Fig. 2E).

We next assessed whether the miR-PE exhibited ability to secret insulin when challenged with high levels of glucose. The miR-PE was subjected to glucose-stimulated insulin secretion assay, by sequential incubation with 2 and 20 mM glucose, in the absence and presence of doxycycline to induce miR-410 expression (Fig. 2F). We found that when challenged with 20 mM glucose, insulin secreted by the miR-PE was increased significantly compared with 2 mM glucose, demonstrating the ability of the miR-PE to produce and secret insulin stimulated by glucose. Of note, insulin secretion of miR-PE in the presence of doxycycline was also markedly higher than that without induction, at both glucose levels (Fig. 2F, \(^{*} P<0.05\)). Further assay confirmed the drop in LDH activity upon doxycycline induction in the miR-PE, compared with the absence of doxycycline (Fig. 2G), which is consistent with previous reports that reduction in LDHA level increased glucose-induced insulin secretion in \(\beta\)-cells (Zhao & Rutter 1998, Ainscow et al. 2000).

**miR-PE transplant alleviated hyperglycemia, hyperinsulinemia, and overweight in pregnant mice**

miR-PE was transplanted under the left kidney capsule of female \(db/+\) mice (see ‘Materials and methods’). Their blood glucose levels, plasma insulin levels, and body weight were measured for all four experimental groups of female mice before PE transplant (day 0), 4 weeks after transplant (day 28), GD0, GD10, and GD20.

Blood glucose levels of all four experimental groups were almost the same prior to pregnancy (Fig. 3A). With the start of pregnancy, blood glucose levels of WT
sham + dox females remained stable. In the meantime as expected, db/+ sham + dox females showed a significant rise in blood glucose levels, presenting the typical GDM symptom of hyperglycemia during pregnancy. Whereas blood glucose levels of db/+ PE -- dox females stayed at significantly lower levels throughout pregnancy than db/+ sham + dox, indicating the alleviating effect on hyperglycemia by the miR-PE transplant. More importantly, in the db/+ PE -- dox group, with doxycycline inducing the expression of miR-410, blood glucose level was as low as the WT sham + dox females, suggesting down-regulation of LDHA by miR-410 in the PE transplant exhibited even more efficacy in treating hyperglycemia.

Plasma insulin levels in all four groups were also very similar before pregnancy (Fig. 3B). However db/+ sham + dox group started producing more insulin after pregnancy, whereas no increase was observed in WT sham + dox and only mild increase in db/+ PE -- dox groups at the same time point. This suggested the PE transplant relieved hyperinsulinemia during pregnancy. As expected, db/+ PE -- dox females exhibited same plasma insulin level as the WT sham + dox control, further demonstrating the
Figure 3
PE transplant alleviated GDM in pregnant mice. Blood glucose levels (A), plasma insulin levels (B), and maternal body weight (C) were measured prior to PE transplant (day 0), 4 weeks after transplant (day 28), and during pregnancy (GD0, 10, and 20) in WT sham + dox, db/+ sham + dox, db/+ PE + dox, and db/+ PE – dox groups. *P < 0.05 db/+ PE + dox vs db/+ PE – dox and db/+ sham + dox at the same time point. **P < 0.05 db/+ PE – dox vs with all the other three groups at the same time point.

extended efficacy of miR-410 expression in alleviating GDM hyperinsulinemia.

Finally, in Fig. 3C, body weight of WT sham + dox increased gradually during the entire span of the experiment. In a sharp comparison, db/+ sham + dox females had much more rapid body weight gain during pregnancy, and db/+ PE – dox females exhibited slightly less weight gain in the same time span, showing the PE transplant was able to efficiently reduce GDM-resulted body weight gain. Again, the body weight of db/+ PE + dox group exhibited the same trend throughout the pregnancy as the WT sham + dox control, both significantly lower than either db/+ sham + dox or db/+ PE – dox, which also suggested down-regulation of LDHA by miR-410 could completely nullify abnormal body weight gain during pregnancy as a result of GDM.

miR-PE transplant maintains fat content, liver weight and TGs, plasma TGs and FFAs, and leptin at baseline levels

We have so far demonstrated consistent results that in pregnant mice, miR-PE transplant that down-regulated LDHA exhibited significant effect in treating GDM-related symptoms, with worst symptoms and maximum alleviating effect towards the end of pregnancy (GD20). Therefore, we next investigated, at GD20, the effect of miR-PE transplant at the organ and tissue development level, since studies have shown underlying correlation between liver weight and obesity in diabetes (Yang et al. 1997). We started with measuring fat content using WT sham + dox group as baseline control and db/+ sham + dox as GDM control. There is no significant difference in fat content between db/+ PE + dox and baseline control, while db/+ PE – dox mice have significantly higher fat content than baseline albeit still lower than GDM control (Fig. 4A). This suggested that mice with miR-PE transplant can better control fat deposition than GDM mice, and achieve even better treatment with miR-410 induction hence LDHA down-regulation.

The liver is a major metabolic tissue for energy homeostasis such as synthesizing TGs de novo from glucose or FFAs obtained from diet and producing very LDL (VLDL) to transport to the circulatory system and eventually to other parts of the animal body (McDevitt et al. 2001, Strable & Ntambi 2010). In this context, liver weight and live TG of mice received miR-PE transplant were also maintained at only slightly higher level than WT sham + dox baseline control, whereas the measurement of db/+ sham + dox mice increased remarkably higher than baseline (Fig. 4B and C). Similarly, inducing miR-410 by administering doxycycline after miR-PE transplant was able to further reduce both liver weight and TG to baseline level.

In the liver, FFAs are produced by the breakdown of TG obtained either from diet or cells like adipocytes as energy source of the body. With adequate plasma, FFAs and TGs from diet, liver synthesizes VLDLs and transports them to adipocytes for storing fat or muscle cells for producing energy. Whereas during fasting, plasma FFA and TG are insufficient to support energy consumption,
miR-PE transplant improved reproductive outcome of GDM females

One reported adverse effect of GDM is fetal mal-development, in that it worsened reproductive outcome in animal model with less fetuses (Siemelink et al. 2002, Buckley et al. 2005). Particularly in db/+ GDM mouse model, fetus weight at term was reported to increase by 5–8% (Lawrence et al. 1989, Yamashita et al. 2001). This has prompted us to investigate whether our miR-PE transplant was able to improve fetal development of GDM female mice.

Total litter number at birth was counted from equal number of dam (n=20) from WT sham + dox (151 litters), db/+ sham + dox (83 litters), db/+ PE + dox (145 litters), and db/+ PE − dox (104 litters) dam groups and plotted in Fig. 5A. Moreover, the mean body weight of litters at birth was also recorded, and we observed that the mean litter weight from db/+ sham + dox and db/+ PE − dox dam groups were significantly higher than that of WT sham + dox, whereas db/+ PE + dox female mice gave birth to litters with nearly the same mean body weight as the WT sham + dox dam (Fig. 5B). Survival rate of litters was also monitored daily during the first 2 weeks (Fig. 5C). Litters born by db/+ sham + dox and db/+ PE − dox dams had significantly higher mortality rate (Fig. 5C, black and blue curves respectively) than the other two groups (red and green curves). These results clearly indicated miR-PE transplant was able to increase the offspring number and the reproductive outcome of GDM female mice.

Discussion

GDM affects nearly 10% of all pregnancies, and females suffering GDM have increased life-long risk of type 2
diabetes (American Diabetes Association 2004). Therefore, studies to understand the underlying mechanism of GDM are of great clinical value. Stem cell therapy utilizing hESCs and hiPSCs have been widely used in animal models and were shown to successfully alleviating diabetic symptoms (Kroon et al. 2008, Pagliuca et al. 2014). These studies have made possible several clinical trials showing promising outcomes in treating diabetes (Viswanathan & Sarang 2013). However, few studies were conducted on GDM in particular, which still focused on dietary intervention method, instead of stem cell therapy or molecular and genetic approaches hence yet provided fruitful results (Landon et al. 2009).

Reasons for the lack of success could be attributed to insufficient experimental data on animal models. Given the relative similar cause and symptoms between type 2 diabetes and GDM, we designed our study by employing stem cell therapy that has previously proven successful, and implementing a miRNA Tet-on inducible system that specifically targets LDHA, whose overexpression affects glucose-induced insulin secretion in β-cells, therefore, is usually kept in check (Sekine et al. 1994). Indeed, we observed an interesting result, that glucose-stimulated insulin secretion of the miR-PE in the presence of doxycycline was markedly higher than that without induction (Fig. 2F). This particular result confirmed previous reports that down-regulation of LDHA level led to elevated insulin secretion upon glucose stimulation in β-cells (Zhao & Rutter 1998, Ainscow et al. 2000). Moreover, in a later part of our study, although in general the PE transplant exhibited alleviation of GDM symptoms, we have consistently observed significant better effects in female mice receiving both miR-PE transplant and doxycycline than those receiving only the PE transplant. We speculate that this improvement in efficacy could be explained by the reduction of LDHA levels in the miR-PE (Fig. 2E), which indicated a potential involvement of LDHA in GDM. There has been no report on the role of LDH in GDM, except that LDHB was found to be down-regulated in adipose tissue from GDM women (Oliva et al. 2013). This and our results suggest a possible distinct regulation of LDHs as well as their roles in contributing to GDM in mammals.

Although sharing the usual suspect of diabetic symptoms, such as hyperglycemia, hyperinsulinemia, overweight, elevated fat content, liver and plasma TG, FFA and leptin levels, GDM is distinct from type 2 diabetes in that GDM also affects reproductive outcome and fetal development (Lawrence et al. 1989, Ishizuka et al. 1999, Yamashita et al. 2001, Siemelink et al. 2002, Buckley et al. 2005). Results from our study were consistent with reports on the same db/+ GDM mouse model, with ~10% increase in body

![Figure 5](http://jme.endocrinology-journals.org)
weight from litters born by GDM dam, whereas miR-PE transplanted GDM females gave birth to litters with body weight comparable to those from WT dam. Therefore, our results supported the potential mechanism where genetic disposition of GDM in pregnant females not only perturbed metabolism during pregnancy, but also adversely affected development and/or metabolism of the fetus, hence abnormally increasing their body weight. Moreover, during the first 2 weeks after birth, litters from db/+ mice exhibited severely reduced survival rate compared to those from the other groups of dams (Fig. 5), suggesting early development of offsprings was also affected by GDM, and more importantly the miR-PE transplant efficient rescued this early developmental defect, which further demonstrated the efficacy of our approach by combined methods.

To summarize, our current study has provided the new method of treating GDM in the db/+ transgenic mouse model, by combining miRNA technique with stem cell therapy. Our results have demonstrated that the miR-PE transplant alleviated hyperglycemia and hyperinsulinaemia in pregnant female mice, and significantly improved their reproductive outcome, as well as early offspring development. Moreover, by inducing the expression of miR-410 to repress LDHA levels in the miR-PE, the effect of the transplant in treating GDM was improved even further. Therefore, our study has provided evidence supporting the potential therapeutic values of not only stem cell therapy, but also incorporation of molecular and genetic modifications to achieve better clinical efficacy in treating GDM in human patients.

Supplementary data
This is linked to the online version of the paper at http://dx.doi.org/10.1530/JME-15-0100.

Declaration of interest
The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research reported.

Funding
This work was supported by Shanxi’s Science and Technology Research Program (2008K14-04).

References


Gil-Campos M, Canete R & Gil A 2004 Hormones regulating lipid metabolism during pregnancy, but also adversely affected the metabolism of the fetus, hence abnormally increasing their body weight. Moreover, during the first 2 weeks after birth, litters from db/+ mice exhibited severely reduced survival rate compared to those from the other groups of dams (Fig. 5), suggesting early development of offsprings was also affected by GDM, and more importantly the miR-PE transplant efficient rescued this early developmental defect, which further demonstrated the efficacy of our approach by combined methods.

To summarize, our current study has provided the new method of treating GDM in the db/+ transgenic mouse model, by combining miRNA technique with stem cell therapy. Our results have demonstrated that the miR-PE transplant alleviated hyperglycemia and hyperinsulinaemia in pregnant female mice, and significantly improved their reproductive outcome, as well as early offspring development. Moreover, by inducing the expression of miR-410 to repress LDHA levels in the miR-PE, the effect of the transplant in treating GDM was improved even further. Therefore, our study has provided evidence supporting the potential therapeutic values of not only stem cell therapy, but also incorporation of molecular and genetic modifications to achieve better clinical efficacy in treating GDM in human patients.

Supplementary data
This is linked to the online version of the paper at http://dx.doi.org/10.1530/JME-15-0100.

Declaration of interest
The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research reported.

Funding
This work was supported by Shanxi’s Science and Technology Research Program (2008K14-04).

References


Received in final form 22 August 2015
Accepted 24 August 2015
Accepted Preprint published online 25 August 2015